A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
An Open-Label, Randomized, Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin in Patients Requiring Second-Line Chemotherapy for Small Cell Lung Cancer That is Refractory or Sensitive to First-Line Platinum-Based Chemotherapy
Sponsor: Taiho Oncology, Inc.
This PHASE2 trial investigates Small Cell Lung Cancer (SCLC) and is currently terminated or withdrawn. Taiho Oncology, Inc. leads this study, which shows 11 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Aug 2017 [monthly]
Terminated PHASE2
First recorded
Jul 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Taiho Oncology, Inc.
- Taiho Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aviano, Italy , Bari, Italy , Berlin, Germany , Catania, Italy , Chiba, Japan , Cremona, Italy , Florence, Italy , Fukuoka, Japan , Großhansdorf, Germany , Hyōgo, Japan and 12 more locations